InnoCare Pharma Limited provided earnings guidance for the year ended 31 December 2023. Based on a preliminary estimate by the finance department, the net loss attributable to owners of the parent company in 2023 is expected to be approximately RMB 656 million, representing a decrease in loss of approximately 26% as compared with the corresponding period of the previous year. The net loss after excluding non-recurring gains or losses attributable to owners of the parent company was approximately RMB 654 million, representing a decrease of approximately 32% as compared with the corresponding period of the previous year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.16 HKD | +1.18% | +0.78% | -25.11% |
13/05 | InnoCare Logs Loss in Q1 | MT |
29/03 | InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.11% | 1.3B | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- 9969 Stock
- News InnoCare Pharma Limited
- InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023